https://www.merck.com/news/mercks-keytruda-pembrolizumab-met-primary-endpoint-of-disease-free-survival-dfs-in-certain-patients-with-muscle-invasive-urothelial-carcinoma-miuc-after-surgery/
0
0
Merck's KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery - Merck
+ 127 more
10/5/23 at 4:00am
Organization
Merck.com
Authors
Details
61 words
Summarize
Cancer Business & Industrial Keytruda Primary Endpoint Merck DFS MIUC Disease-Free Survival Urothelial Carcinoma NYSE
KEYTRUDA significantly improved DFS as adjuvant therapy versus observation for patients with localized MIUC and locally advanced urothelial carcinoma First positive study for KEYTRUDA as adjuvant therapy for these patients Merck (NYSE: MRK), known as MSD outs…
Create an account or login to join the discussion